Delta and Lambda SARS-CoV-2 Variants: Current Evidence .

The Delta variant’s rise underscores its high transmissibility, with global data showing rapid displacement of earlier SARS-CoV-2 lineages. Despite some reduction in vaccine performance, evidence consistently demonstrates that Pfizer-BioNTech, Moderna, and AstraZeneca vaccines maintain strong protection against severe Delta-related outcomes, including hospitalization. Early laboratory studies on the emerging Lambda variant show it remains susceptible to vaccine-elicited antibodies, though neutralization titers drop several-fold. While these findings are reassuring overall, they highlight a familiar theme: variants will continue to evolve, making sustained vigilance and broad vaccination essential in maintaining control of COVID-19.